Clinical trial
A Study to Test Efficacy and Safety of Rozanolixizumab in Adult Patients With…
NCT03971422 · UCB Biopharma SRL, Industry · Completed
Key facts
| NCT number | NCT03971422 |
|---|---|
| Title | A Study to Test Efficacy and Safety of Rozanolixizumab in Adult Patients With Generalized Myasthenia Gravis |
| Official title | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating Efficacy and Safety of Rozanolixizumab in Adult Patients With Generalized Myasthenia Gravis |
| Lead sponsor | UCB Biopharma SRL, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Generalized Myasthenia Gravis |
| Intervention type | Drug, Other |
| Interventions | Rozanolixizumab, Placebo |
| Enrollment | 200 |
| Start date | Jun 3, 2019 |
| Primary completion | Aug 31, 2021 |
| Completion | Oct 26, 2021 |
| First posted | Jun 3, 2019 |
| Last update posted | Dec 24, 2025 |
| Countries | Belgium, Canada, Czechia, Denmark, France, Georgia, Germany, Hungary, Italy, Japan, Poland, Russia and 5 more |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: